B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

Citation for published version:

Digital Object Identifier (DOI):
10.1084/jem.20111675

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Journal of Experimental Medicine

Publisher Rights Statement:
Free in PMC.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

Tom A. Barr,1,2 Ping Shen,5 Sheila Brown,1,2 Vicky Lampropoulou,5 Toralf Roch,5 Sarah Lawrie,6 Boli Fan,7 Richard A. O’Connor,2,3,4 Stephen M. Anderton,2,3,4 Amit Bar-Or,6,7 Simon Fillatreau,5 and David Gray1,2

1Institute of Immunology and Infection Research and 2Centre for Immunology, Infection and Evolution, School of Biological Sciences, and 3Centre for Multiple Sclerosis Research, University of Edinburgh, Edinburgh EH8 9UL, Scotland, UK
4Medical Research Council Centre for Inflammation Research and 5Centre for Multiple Sclerosis Research, University of Edinburgh, Edinburgh EH8 9UL, Scotland, UK
6Neuroimmunology Unit and 7Experimental Therapeutics Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec H3A 2B4, Canada

B cells have paradoxical roles in autoimmunity, exerting both pathogenic and protective effects. Pathogenesis may be antibody independent, as B cell depletion therapy (BCDT) leads to amelioration of disease irrespective of autoantibody ablation. However, the mechanisms of pathogenesis are poorly understood. We demonstrate that BCDT ameliorates central nervous system autoimmunity through ablation of IL-6–secreting pathogenic B cells. B cells from mice with experimental autoimmune encephalomyelitis (EAE) secreted elevated levels of IL-6 compared with B cells from naive controls, and mice with a B cell–specific IL-6 deficiency showed less severe disease than mice with wild-type B cells. Moreover, BCDT ameliorated EAE only in mice with IL-6–sufficient B cells. This mechanism of pathogenesis may also operate in multiple sclerosis (MS) because B cells from MS patients produced more IL-6 than B cells from healthy controls, and this abnormality was normalized with B cell reconstitution after Rituximab treatment. This suggests that BCDT improved disease progression, at least partly, by eliminating IL-6–producing B cells in MS patients. Taking these data together, we conclude that IL-6 secretion is a major mechanism of B cell–driven pathogenesis in T cell–mediated autoimmune disease such as EAE and MS.

Recent studies have shown that B cell depletion therapy (BCDT) can efficiently reduce disease progression in relapsing-remitting multiple sclerosis (RR–MS) and in experimental autoimmune encephalomyelitis (EAE; Bar-Or et al., 2008; Hauser et al., 2008; Matsushita et al., 2008). Thus, in addition to their documented regulatory capacity (Mauri et al., 2003; Mann et al., 2007; Fillatreau et al., 2008; Lampropoulou et al., 2008), B cells also promote the inflammatory response in EAE and MS (Anderton and Fillatreau, 2008; Lampropoulou et al., 2010). RR–MS is a chronic inflammatory demyelinating disease of the central nervous system (CNS) associated with an accumulation of immune cells at lesion sites. Although polymorphisms in genes controlling T cell activation show the strongest association with disease susceptibility (Oksenberg et al., 2008), B cell activation is also a common abnormality in RR–MS, highlighted by the presence of intrathecal oligoclonal immunoglobulin bands in >90% of patients (Fillatreau and Anderton, 2007). It is therefore clear that B cells participate in this disease. However, the mechanisms by which B cells exert pathogenic effects in RR–MS are not understood.

B cells might promote tissue destruction through autoantibody production in RR–MS (Wekerle, 1999). Myelin-reactive autoantibodies are sometimes found in serum and CNS of RR–MS patients, and transduction of autoantibody-containing serum exacerbates demyelination.
and axonal loss in rats (Zhou et al., 2006). However, clinical improvement in patients treated with Rituximab often precedes reduction in autoantibody levels (Edwards and Cambridge, 2006; Martin and Chan, 2006). More importantly, treatment with Atacicept, which reduces numbers of short- and long-lived plasma cells (Baláz et al., 2002; O’Connor et al., 2004; Belnoue et al., 2008), resulted in aggravation, not improvement, of RR–MS (Hartung and Kieseier, 2010). These observations concur to indicate that B cells propagate this autoimmune disease via antibody-independent mechanisms. If antibody is not the principal mediator of B cell pathogenesis, then we must ask what other aspects of B cell function are important? Rituximab treatment results in a noticeable decline of T cell numbers in CNS of treated patients (Cross et al., 2006), suggesting that B cells facilitate RR–MS progression by sustaining pathogenic T cell responses, possibly through presentation of antigen and/or secretion of cytokines (Bar-Or et al., 2010). The latter mechanism attracted our interest because cytokine blockade is often an effective treatment for autoimmune disease (Bar-Or et al., 2010). Furthermore, cytokines can be elicited from B cells irrespective of antigenic specificity (e.g., Toll-like receptor [TLR]–activated B cells, microbe–specific B cells, or B cells reactive to other antigens). Antigen presentation to encephalitogenic T cells, in contrast, can be performed only by myelin–specific B cells. This is a highly pertinent consideration because an important proportion of the B cell response is not myelin reactive in RR–MS (Ovens et al., 2009). A candidate cytokine for the pathogenic functions of B cells in RR–MS is IL-6, which is essential for the development of EAE (Eugster et al., 1998; Mendel et al., 1998; Okuda et al., 1998; Samoilova et al., 1998), the primary mouse model of RR–MS. B cells can secrete large amounts of IL-6 in response to polyclonal activating stimuli and subsequently enhance T cell proliferation in vitro (Lampropoulou et al., 2008) and Th17 responses in vivo (Barr et al., 2010), which have a pathogenic role in autoimmune disease (Korn et al., 2009). Based on this rationale, we evaluated the role of IL-6 production by B cells in EAE and MS.

RESULTS
B cells are a major source of IL-6, which is stimulatory for T cells

We first sought to determine the relative contribution of B cells to total IL–6 production in vivo. To address this, naive mice were ablated of B cells using anti-CD20. Whole (unsorted) spleen and lymph node cell cultures were then stimulated with LPS, CpG, and anti-CD40, which engage major receptors involved in activation of APCs. Anti-CD20 therapy depleted B cells with 95% or greater efficiency, with the knock–on consequence of enriching innate APC and T cells in the cultures (unpublished data). Despite this enrichment in many potential sources of IL–6 (e.g., macrophages, dendritic cells, neutrophils, and T cells), IL–6 production was massively reduced after anti-CD20 depletion (Fig. 1 A), and B cells accounted for 65–95% of IL–6, and, therefore, appeared to be a major source of IL–6 in secondary lymphoid tissues.

In RR–MS, the disease–promoting activity of B cells might be related to a stimulatory effect on pathogenic T cells (Cross et al., 2006). We therefore tested if B cells could modulate T cell responses through IL–6. Naïve T cells were stimulated in vitro in the presence of supernatants from B cells activated with LPS+CD40. Remarkably, T cell proliferation was significantly enhanced by supernatants from WT B cells (even though they were diluted at least fivefold) but not from IL–6–deficient B cells (Fig. 1 B; P = 0.0053 by two–way ANOVA). We next evaluated the capacity of various B cell subsets to secrete IL–6. Marginal zone (MZ), follicular (FO), and transitional (TN) B cell subsets were sorted by flow cytometric sorting based on expression of CD19, CD21, CD23, and CD1d. MZ B cells (CD21hiCD23lo or CD1d+) rapidly secreted IL–6 in response to TLR4 stimulation with LPS, and the amount of IL–6 produced was further increased to ~4 ng/ml by provision of surrogate T cell help, in the form of anti–CD40 (Fig. 1 C). Intriguingly, this same subset also secreted the greatest amounts of IL–10, as we have reported previously (Barr et al., 2007; Lampropoulou et al., 2008; Fig. 1 C), although it is noteworthy that the signals driving maximal levels of these cytokines are distinct (i.e., IL–6 with CpG and IL–10 with LPS). The difference in IL–6 production across various B cell subsets was less apparent in longer term cultures (72 h stimulation; unpublished data).

To investigate whether B cells might contribute to EAE pathogenesis—which is T cell mediated—through production of IL–6, we first sought to determine if IL–6 production by B cells was increased during EAE. CD19+ B cells were isolated from naive mice, and from mice with EAE by magnetic and FACS sorting. IL–6 mRNA was expressed at significantly higher levels in B cells from EAE mice compared with B cells from naive animals (Fig. 1 D; P = 0.035 by Student’s t test). Given our demonstration that MZ/CD1d+ B cells represent the most significant source of B cell–derived IL–6, we next assessed the composition of the B cell compartment during the EAE response. The frequency of MZ B cells in EAE mice was elevated from day 14 onwards (Fig. 1 E). To assess the capacity of individual subsets to produce IL–6 in EAE, mRNA was quantified on FACS–sorted samples. Increased IL–6 mRNA expression was most noticeable in MZ (CD21hiCD23lo; P = 0.0244) and TN (CD21loCD23lo; P = 0.024) but not in FO (CD21loCD23hi) B cell subsets (Fig. 1 F). Thus, both frequency of IL–6 producers and capacity of these subsets to produce IL–6 are elevated in EAE. As with naive mice (Fig. 1 A), B cells from EAE mice were found to be the major source of IL–6 in responses to TLR stimulation, as whole cell cultures from CD20–depleted animals with EAE showed up to 86% reduction in IL–6 secretion (Fig. 1 G). Increased IL–6 production by B cells is not restricted to CNS autoimmunity. B cells from mice immunized with a nonpathogenic peptide antigen (chicken egg OVA, POVA) in complete Freund’s adjuvant showed similarly increased IL–6 secretion (unpublished data). We have also previously shown that B cells secrete elevated IL–6 during Salmonella infection (Barr et al., 2010). Thus, it appears that B cells respond via innate receptors rather than via antigen–specific BCR. Indeed, stimulation of B cells from myelin...
generated mixed bone marrow chimeric mice with a B cell–specific deficiency in IL-6 production (B-IL-6−/−), together with control chimeras (B-WT). The validation of these chimeras is outlined in Fig. 2A. Of note, B-IL-6−/− mice contain a 20% IL-6 deficiency in all hematopoietic cells, in addition to a complete lack of IL-6 production by B cells. To control for the effect that such deficiency outside the B cell compartment could have on the disease course, we generated IL-620% chimeras, which have 20% IL-6 deficiency in all hematopoietic compartments, including in B cells. After 8–10 wk of reconstitution, chimeric mice were immunized with MOG to induce EAE. All groups of mice started to display disease signs with similar kinetics (mean day of disease onset

Mice with a B cell–specific IL-6 deficiency develop an attenuated form of EAE

We next asked whether IL-6 production by B cells contributed to disease pathogenesis during EAE. To this end, we
B–WT = 9.2 ± 0.3, B–IL–6−/− = 9.0 ± 0.3, and IL–620% = 8.5 ± 0.3), indicating that IL–6 production by B cells was not required for initiation of the pathogenic process. However, B–IL–6−/− mice showed a markedly lower maximal disease score than control groups (B–IL–6−/− = 3.8 ± 0.2, IL–620% = 4.8 ± 0.3, and B–WT = 5.1 ± 0.3), implying that B cells drive disease exacerbation through the production of IL–6. Reflecting this, fewer B–IL–6−/− mice reached a disease severity imposing sacrifice (because of ethical regulations) compared with B–WT or IL–620% mice (P = 0.0077 and P = 0.1830, respectively; Fig. 2 C). In addition, B–IL–6−/− mice showed a better recovery from disease than the two control groups (Fig. 2 B). B–IL–6−/− mice also appeared to suffer a less severe EAE than B–WT mice when comparing global disease burdens. In such comparison, IL–620% mice also displayed a slightly milder overall disease than B–WT mice (P < 0.001), but the difference was clearly stronger for B–IL–6−/− mice (P < 0.001 B–IL–6−/− vs. B–WT, P < 0.001 B–IL–6−/− vs. IL–620%), indicating that lack of IL–6 production by B cells was the major cause of
disease attenuation in B-IL-6−/− mice. Collectively, our results show that B cells specifically exacerbate ongoing disease through IL-6 production.

**BCDT acts by eliminating IL-6 production by B cells, irrespective of its effects on MOG-reactive antibodies.**

B cells might contribute to autoimmune pathogenesis via several mechanisms, in addition to IL-6 secretion, including through production of antibodies or other inflammatory cytokines. To test the importance of IL-6 production in the pathogenic functions of B cells during EAE, we treated B-IL-6−/− and B-WT chimeric mice with a B cell–depleting anti-CD20 antibody after initiation of disease. As previously described (Matsushita et al., 2008), such anti-CD20 treatment resulted in a marked amelioration of disease in mice with WT B cells (Fig. 3 A; B-WT, P < 0.0001; IL-620%, P < 0.0001). We then asked if this effect was related to the elimination of IL-6 production by B cells by treating B-IL-6−/− mice with anti-CD20 (Fig. 3 A). Remarkably, depletion of B cells had no impact on disease severity in B-IL-6−/− chimeras, suggesting that BCDT works primarily by eliminating IL-6–producing B cells. We then measured antibody responses in isotype control and anti-CD20–treated animals. Total MOG-specific antibody levels were similarly reduced in all the groups of chimeras treated with anti-CD20, irrespective of improvement of disease outcome (Fig. 3 B). This applied to all detectable antibody isotypes (IgG1 and IgM; unpublished data). From these results, we conclude that BCDT in mice acts through abrogating IL-6 production by B cells. The B cell IL-6–dependent mechanism of pathogenesis was unrelated to antibody production because mice with WT or IL-6−/− B cells produced similar amounts of MOG-reactive antibodies during EAE.

**Ameliorated EAE in B-IL-6−/− chimeras is associated with a reduced Th17 response**

IL-6 has a critical role for the maintenance of Th17 cells (Korn et al., 2009), a T cell subset implicated in pathogenesis of EAE (Bettelli et al., 2006). We tested the impact of IL-6...
production by B cells on the Th17 response during EAE. Intracellular cytokine staining of splenic cells from mice with EAE ex vivo revealed a significantly impaired IL-17 production by T cells in B-IL-6−/− mice, compared with B-WT controls (Fig. 4, A and B; P = 0.0236), whereas IFN-γ secretion was unaffected. The reduction in IL-17 expression was not complete, indicating that other cells and factors also contributed to Th17 polarization in this model, besides IL-6–producing B cells. In addition to ex vivo intracellular cytokine, we also restimulated purified splenic CD4+ T cells from EAE mice with MOG in the presence of WT irradiated APC. In agreement with the ex vivo data, T cells from B-IL-6−/− mice secreted less IL-17 than those from B-WT chimeras, whereas levels of IFN-γ were equivalent (Fig. 4 C; P = 0.0094). Given the modest reduction in IL-17 production by CD4+ T cells in B-IL-6−/− mice, we also quantified ex vivo expression of the Th17 master regulator RORγt by intracellular staining on circulating CD4+ T cells. In accordance with the secretion of IL-17 by splenic T cells, expression of RORγt was significantly reduced in B-IL-6−/− chimeras (Fig. 4 D). Intriguingly, Tbet expression was also impaired, whereas FoxP3 expression was not. This effect on T cell IL-17 production was noticeable systemically, in the spleen and in the blood. Although there was a trend toward reduced Th17 cells, numbers in the CNS and draining LN of B-WT and B-IL-6−/− mice at the peak of disease (day 14), and upon recovery (day 32) were not statistically different (unpublished data). We then asked if B cells also promoted Th17 responses in response to a distinct non–self-antigen such as OVA. For this purpose, transgenic OVA-specific DO11.10 CD4+ T cells were adoptively transferred into WT or B cell–deficient Jp0D hosts, and IL-17 expression by antigen-reactive CD4+ T cells was measured by flow cytometry after immunization with OVA. In agreement with the data obtained with MOG, DO11.10 T cell expression of IL-17 was greatly impaired in B cell–deficient mice, whereas IFN-γ was not affected (Fig. 4 E; P = 0.0017). Collectively, these data reveal that IL-6–producing B cells have an essential role in the propagation of Th17 responses in vivo, which might exacerbate CNS pathogenesis during EAE.

**B cells from RR-MS patients secrete elevated levels of IL-6, which is reduced after BCDT.**

In our final series of experiments, we investigated the relevance of our findings on IL-6 production by B cells in EAE for the corresponding human disease, namely RR-MS. To achieve this, we isolated peripheral blood B cells from patients with RR-MS and healthy controls. After stimulation in vitro by engagement of BCR and CD40, with or without CpG DNA, IL-6 was quantified by ELISA. We found that B cells from RR-MS patients secreted IL-6 at four- to fivefold higher levels than B cells from healthy controls (Fig. 5 A; P = 0.0275). In a separate longitudinal study of RR-MS patients before and after BCDT with Rituximab, we found that B cells returning after depletion secreted reduced levels of IL-6, comparable with the healthy control group (Fig. 5 B; pre-Rtx vs. post-Rtx, P = 0.0349; pre-Rtx vs. HC, P = 0.0185; post-Rtx vs. HC, P = 0.1763). Finally, we tested IL-6 production in PBMC from RR-MS patients depleted of B cells or not, and found, in accordance with our EAE studies, that B cell depletion led to a reduced IL-17 response without having an impact on IFN-γ production (Fig. 5 C; IL-17, P = 0.0400; IFN-γ, P = 0.7104). Collectively, these data suggest that, as in EAE, B cells contribute to pathogenesis of RR-MS through production of IL-6.

**DISCUSSION**

In the clinic, BCDT can markedly ameliorate the course of autoimmune diseases in patients, but the mechanisms underlying these beneficial effects are poorly understood, as they are thought, in many cases, to operate irrespective of autoantibody levels. Here, we demonstrate that IL-6 production is the major mechanism of B cell–mediated pathogenesis during EAE, and we show that this inflammatory pathway is markedly increased in RR-MS patients. Autoantibody levels were unaffected by IL-6 production by B cells. This is the first demonstration of a nonantibody–mediated mechanism of B cell pathogenesis in EAE and MS. Remarkably, the elevated...
production of IL-6 by B cells from MS patients was effectively normalized by Rituximab treatment. In both patients and mice the reduced disease severity after B cell depletion was accompanied by a decrease in the autoreactive Th17 response, and so we believe that B cells are making an all-important contribution to the IL-6–dependent promotion of pathogenic Th17 differentiation (Bettelli et al., 2006). The role of IL-17 in EAE/MS pathogenesis has undergone controversy (Komiyama et al., 2006; Haak et al., 2009) since the first observation (Bettelli et al., 2006); however, the current consensus is that Th17 as well as Th1 cells contribute to disease progression (Kroenke et al., 2008; O’Connor et al., 2008; Zepp et al., 2011). We should also not forget that IL-6 has many other actions that contribute to pathology in autoimmune or chronic inflammatory conditions (Neurath and Finotto, 2011), but we do not know yet if B cell–derived IL-6 contributes more widely to pathogenesis than supporting the Th17 response. This seems likely, as IL-6 controls proliferation and resistance to apoptosis of activated T cells (Neurath and Finotto, 2011), it switches off the suppressive effects of T reg cells (Pasare and Medzhitov, 2003), and IL-6 blockade inhibits the development of myelin-specific Th1 as well as Th17 cells in EAE (Serada et al., 2008). Of note, B cells can also secrete other proinflammatory cytokines in RR-MS (Duddy et al., 2007; Bar-Or et al., 2010), and it will be important to evaluate directly the pathogenic contribution of these functions to the disease process in future studies, even though our data clearly emphasize IL-6 as a major B cell–derived driver of disease.

Interestingly, the B cell IL-6 response does not influence the onset of EAE, suggesting a later acting role. The late contribution of B cells to pathogenesis coincides with the expansion of CD1d<sup>+</sup> MZ B cells, the most potent producers of B cell–derived IL-6. In contrast, we have previously shown that the B cell IL-10 response and regulatory function is set up early during immune responses, in both autoimmune and infection models (Lampropoulou et al., 2008; Barr et al., 2010; Neves et al., 2010). This early IL-10 response sets up the opportunity of a negative feed-forward loop, and this not only has the benefit of preventing excessive inflammation but also, surprisingly, of accelerating the immune response (Lampropoulou et al., 2010; Neves et al., 2010). We have proposed that an impairment or lack of this early-acting B cell regulation is the reason why autoimmune activation leads to chronic non-resolving lesions that progress to full-blown disease (Fillatreau et al., 2008). The prediction of an imbalance in the B cell cytokine response in autoimmune conditions is borne out by the observation that B cells from MS patients make less IL-10 (Duddy et al., 2007). Another aspect of this imbalance can be seen here in MS patients compared with healthy volunteers and also in the patients after BCDT. The levels of IL-6 made by B cells from MS patients are much higher than from healthy volunteers and there is a dramatic fall to normal IL-6 secretory activity after BCDT. This would suggest that the B cells repopulating after Rituximab are normal and have not been influenced by conditions that led to the pathogenic cytokine imbalance. In other words, the B cell cytokine response has been reset. As memory B cells have been reported to secrete elevated levels of IL-6 (Burdin et al., 1995; Good et al., 2006; Cognasse et al., 2008), a speculative interpretation would be that alleviation of disease by BCDT is associated with depletion of these cells. The phenotype and repopulation kinetics of this patient cohort have been previously published, and they show that the B cells reemerging after BCDT are almost exclusively naive CD27<sup>−</sup> cells (Duddy et al., 2007). However, frequencies of CD27<sup>+</sup> cells before depletion were similar between healthy controls and MS patients, and so elevated IL-6 in MS patients may not be solely attributed to the frequency of this subset. Future studies are aimed at identifying the IL-6–producing cells in humans. Whether this resetting of the B cell cytokine environment will be lasting or short-lived still needs to be investigated. We suggest that measuring IL-6 production by B cells from patients might be a useful means for predicting (and monitoring) their response to BCDT.

The role of B cells in the generation and maintenance, but also control of pathogenic T cell responses in autoimmunity is a complex one that we have barely begun to understand. One issue is whether particular subsets of B cells have specific roles to play. However, in the area of regulation where most work has been done, there is a lack of clarity. The so-called B reg cells identified by some groups (e.g., B10 cells [Yanaba et al., 2008] or TN B cells [Blair et al., 2010]) may simply represent the most active IL-10 producers ex vivo; however, under stimulatory or inflammatory conditions other cells may come into play in vivo (e.g., MZ B cells, plasmablasts, or human memory-type cells [Barr et al., 2007; Lampropoulou et al., 2008; Bouazizi et al., 2010; Neves et al., 2010]). In this study, we find that the very same cells, namely CD1d<sup>+</sup> MZ B cells, can produce IL-6 and IL-10 upon short-term stimulation in vitro. Our data suggest that the same B cells might promote either pathogenesis or regulation depending on the prevailing immunological context in which they find themselves (Gray and Gray, 2010; Lampropoulou et al., 2010). A possible scenario could be that in vivo the pathogenic (IL-6) and regulatory (IL-10) responses are generated with different kinetics as a result of stimuli dose variations or the combinatorial quality of the signals driving one or other response. Of particular note is the role of CD40 stimulation in IL-6 and IL-10 production by B cells. IL-6 is augmented by CD40 stimulation, whereas IL-10 is inhibited. This suggests that B cells responding solely to TLRs become regulatory, whereas upon receiving T cell help B cells promote inflammation through secretion of IL-6. With human B cells, IL-10 may also be augmented by CD40 stimulation (Burdin et al., 1995), and so it will be important to ascertain the stimuli that lead to IL-6 expression in vivo. Thus we propose that B cells become inflammatory only upon interaction with appropriately primed helper T cells (i.e., late in the response) and regulatory in the absence of specific T cell help (i.e., early in the response).

With regard to the signals that drive different B cell cytokine responses in vivo during disease induction no comprehensive study exists, the closest is a study published by Duddy et al. (2007) comparing patients with RR-MS and controls.
Interestingly, they find that the IL-10 derives from naive B cells as opposed to activated/memory B cells, whereas the converse is true of the inflammatory cytokines such as TNF and lymphotixin. This study of MS patients (Duddy et al., 2007) used signals mimicking adaptive stimuli (anti-BCR and anti-CD40), and in mice with EAE, it is also true that the regulatory B cell IL-10 response required T cell–derived (CD40L) and antigen–specific signals (Fillatreau et al., 2002). However, the production of IL-10 in mice (Lampropoulou et al., 2008; Barr et al., 2010; Neves et al., 2010) and humans (Bouaziz et al., 2010) is strongly augmented by TLR signals and, indeed, these innate signals are required in vivo for the full expression of regulatory activity (Lampropoulou et al., 2008; Neves et al., 2010) and T cell programming by B cells in general (Barr et al., 2010). We know less about the control of the B cell IL-6 response; however, it seems to mirror the IL-10 response in that it is elicited both by innate and adaptive stimuli and it is secreted most actively by cells within the same subpopulation (MZ). In the experiments shown here and in previous studies (Barr et al., 2007; Lampropoulou et al., 2008), anti-CD40 and TLR signals (LPS) synergize in their stimulation of IL-6 secretion. Intriguingly, no signal has been identified that selectively instructs pro– or anti–inflammatory functions in B cells. We have previously shown that B cells activated via TLR produce a cytokine milieu that can inhibit T cell stimulation by dendritic cells (via IL-10) while facilitating T cell activation by anti-CD3 (via IL-6; Lampropoulou et al., 2008). Activated B cells can therefore concomitantly secrete cytokines having opposite effects on immune responses so that their net influence on immunity profoundly depends on their immediate cellular microenvironment, which is likely to change during the course of the immune response.

Our findings might be particularly relevant for treatment of RR–MS. Both IFN-β and glatiramer acetate therapies induce increased IL-10 secretion by B cells (Kala et al., 2010; Ramgolam et al., 2011), suggesting that part of their beneficial effects relates to tipping the balance from pathogenic to regulatory B cell function. IFN-β has broader effects on cytokine production by B cells, reducing their secretion of IL-1β and IL-23 while increasing expression of IL-12 and IL-27 (Ramgolam et al., 2011), an activity likely to reduce Th17 differentiation. Our study supports the notion that the pathogenic role for B cells in MS (and other autoimmune diseases) relates largely to the production of cytokines (Bar-Or et al., 2010). Here, we demonstrate that IL-6 production is a primary mechanism of B cell–mediated pathogenesis during EAE, and we provide evidence that this inflammatory pathway is profoundly deregulated in RR–MS. It will be important to evaluate whether current RR–MS therapies modulate the production of IL-6 by B cells during RR–MS. Remarkably, the repopulating B cells after BCDT no longer have a pathogenic cytokine profile, suggesting that the mode of action of such treatment relies on the elimination of inflammatory B cell activities. Novel approaches that selectively modulate cytokine production by activated B cells might provide interesting alternatives to control pathogenic inflammation in autoimmune diseases.

### MATERIALS AND METHODS

**Mice.** Mice were bred and maintained in specific pathogen-free conditions at the School of Biological Sciences facility at the University of Edinburgh. Mice were aged 6–8 wk at the start of procedures. Experiments were covered by a UK Home Office Project License, granted under the Animal (Scientific Procedures) Act 1986 and approved locally by the University of Edinburgh Ethical Review Committee.

**B cell subset sorting and stimulation.** B cells were isolated by CD43 depletion from spleens of naive or EAE day 14 mice, using MACS magnetic beads (Miltenyi Biotec). The negative fraction was stained with CD19, CD21, CD1d, and CD23, and then FACS sorted for MZ, FO, and double-negative TN populations. 5–10 × 10^6 cells were lysed by RINazol extraction and cDNA synthesis. 5 × 10^5 cells per well were stimulated with 5 µg/ml LPS or 10 µg/ml anti-CD40, in combination or alone. Controls cells were left unstimulated. Supernatants were harvested 24 or 72 h later. The following primers were used for RT-PCR: actin sense, 5′-TGAATCTCTGGGAATCGTGGA-3′; actin antisense, 5′-TAAAGCCAGCCTCAATGACTCC-3′; IL-6 sense, 5′-GTTTCTCTGGGAAATCGTGGA-3′; IL-6 antisense, 5′-TTACCTCAGCTATTGCTTG-3′; IL-10 sense, 5′-AGCCGGAAAGACATATAACTG-3′; and IL-10 antisense, 5′-CATTTCGATAAGGCTTG-3′.

**Mixed bone marrow chimeras.** Mice with a B cell–specific IL-6 deficiency were generated using the mixed bone marrow chimeras system as described previously (Fillatreau et al., 2002; Barr et al., 2010). In brief, irradiated μMT mice were reconstituted with a mixed inoculum of bone marrow (20% IL-6−/− or WT and 80% μMT). The hematopoietic compartment was left for 8–10 wk to repopulate. Thus, all B cells arising from these inocula originated from the IL-6−/− (or WT) portion, with all other hematopoietic lineages deriving predominantly from the μMT portion (i.e., IL-6 sufficient). These mice were designated B-IL-6−/− and B-WT chimeras. To control for a partial IL-6 deficiency in the non-B cell compartment, a control group with a 20% deficiency in all hematopoietic cells was made (designated IL-60/−). Chimerism was confirmed by IL-6 ELISA on supernatants from MACS sorted B cell (CD43+) and non–B cell compartments (CD43−) after PM and ionomycin stimulation. Characterization of chimeras is outlined in Fig. 2 A.

**Induction of EAE.** Mice were immunized subcutaneously with 100 µg MOG (35–55) peptide emulsified in complete Freund’s adjuvant and 200 μg pertussis toxin (Ptx) intraperitoneally on day 0, as previously described (Fillatreau et al., 2002). Mice received a second dose of Ptx 2 d later. Clinical signs of EAE were assessed as follows: 0, no signs; 1, flaccid tail; 2, impaired gait/righting reflex; 3, partial hind limb paralysis; 4, total hind limb paralysis; 5, hind limb paralysis with partial front limb paralysis; 6, moribund or dead.

**Mouse B cell depletion.** The anti-CD20 antibody 18B12 and its isotype control (IgG2a) were provided by M. Kehry and R. Dunn (Biogen Idec, Weston, MA). B cells were depleted with a single 250 µg dose via the intravenous route at day 10. Depletion was confirmed by staining circulating CD19+ cells in blood taken 14–21 d after EAE induction.

**Intracellular cytokine staining.** Splenocytes from EAE mice were stimulated with 10 ng/ml PMA and 1 µg/ml ionomycin (Sigma-Aldrich) in the presence of 1 µg/ml brefeldin A (GolgiStop; BD) for 4 h. Cells were washed in FACS buffer (PBS, 2% FCS, and 0.02% NaN₃) and stained for CD4 (GK1.5, BioLegend). Samples were treated with fixative/permeabilization buffer (BD) and then stained with anti–IFN-γ (XMG1.2) and anti–IL-17 (TC11.18H10; BioLegend). Samples were acquired using FACSComp and LSR-II flow cytometers (BD). Data were analyzed using FlowJo software (Tree Star).

**In vitro restimulation assays.** 10^6 cells/ml MACS–sorted CD4+ T cells from spleens of EAE mice were cultured with 30 µM anti-CD3 (via IL-6; Lampropoulou et al., 2008) and B-WT chimeras. To control for a partial IL-6 deficiency in the non-B cell compartment, a control group with a 20% deficiency in all hematopoietic cells was made (designated IL-60/−). Chimerism was confirmed by IL-6 ELISA on supernatants from MACS sorted B cell (CD43+) and non–B cell compartments (CD43−) after PM and ionomycin stimulation. Characterization of chimeras is outlined in Fig. 2 A.
commercially available antibody sets for IL-6, IL-10, IL-17, and IFN-γ in accordance with the manufacturer’s instructions.

**RR-MS patient study groups.** All patients in this study were participants in the clinical trial program of Rituximab in MS and were subject to inclusion criteria outlined previously. These include the phase II placebo controlled study by Hauser et al. (2008) and the open-label phase I RR-MS study by Bar-Or et al. (2008). These placebo-controlled randomized trials were performed at 32 different centers in the United States and Canada. Protocols were approved by the institutional review board and the ethics reviews committee of each institution. For Fig. 5 A, there were five female (aged 26, 28, 37, 51, and 66 yr) and three male (aged 27, 33, and 51 yr) patients, with the same number of age-sex-matched healthy control volunteers. For Fig. 5 B, there were seven female (aged 55, 42, 61, 49, 52, and 39 yr) and five male (aged 51, 59, 28, and 54 yr) patients. Patients were not HLA typed and were receiving no treatments other than Rituximab.

**Rituximab treatment of RR-MS.** Patients were given two infusions of 1,000 mg Rituximab, 2 wk apart, and then followed prospectively. CD19+ B cells were isolated from PBMC obtained from the patients before treatment with Rituximab and at 12 mo after treatment as outlined in the next section.

**Human PBMC cultures.** Human B cells and PBMC were isolated and stimulated as previously described (Duddy et al., 2007). In brief, after FicollPlaque separation and CD19+ MACS sorting, B cells were plated at 7.5 × 10^4 cells/ml in a total volume of 200 µl. The cells were cultured with CD154-transfected L cells together with anti-B-CR (cross-linking anti-lgM/lgG), with and without the addition of CpG DNA. After 3 d, supernatants were harvested for cytokine analysis by ELISA. Cytokine production was assessed by ELISA using OpTEIA ELISA kits (BD).

**Adoptive transfer of DO11.10 T cells.** T cells from spleens of pOVA-specific transgenic mice (DO11.10) were sorted by CD4+ selection using MACS. 10^6 cells were injected intravenously into BALB/c or B cell-deficient hosts (J6-12D). Animals were immunized subcutaneously with 100 µg pOVA emulsified in CFA 24 h later. Animals were sacrificed 5 d after immunization, and cytokines were quantified in splenocytes by flow cytometry as outlined in Intracellular cytokine staining. Transferred T cells were identified using the anti-idiotypic antibody KJ1.26.

**Statistics.** Student’s t test and Mann Whitney U test were used to calculate p-values between groups with normal and non-Gaussian distributions, respectively. Comparison between three or more groups was by one-way ANOVA with Bonferroni’s post-test analyses. Where comparing curves with two variables (e.g., time and disease score) two-way ANOVA was used. Survival curves were analyzed by log-rank test.

We would like to thank Marilyn Kehry (Biogen Idec) for provision of the anti-CD20 antibody. We also thank members of the Experimental Therapeutics Program at the Montreal Neurological Institute.

This work was funded by the Wellcome Trust (D. Gray), Hertie Stiftung and the Medical Research Council (S.M. Anderton).

**References**


